GLP-1 drugs (Novo Nordisk’s Ozempic; Eli Lilly’s Trulicity) are a new class of medication for treating people with diabetes and are now routinely recommended in high-income countries. However, these drugs are currently unavailable in low and middle-income countries (LMICs.)
Also, insulin pen injection devices, which are safer and have more dosing accuracy than traditional syringes and vials, are routinely used in high-income countries, but due to high prices, are almost never available to people in LMICs.

MSF Access Campaign published a report revealing a dramatic markup on the prices of new diabetes medicines and insulin pens, highlighting the corporate profiteering on these lifesaving medical tools.

These infographics summarise the findings of the report.

Link to asset templates - https://www.canva.com/design/DAGCp5CMBEs/o9n0goBMslitRs9eaiJDrg/view?utm_content=DAGCp5CMBEs&utm_campaign=designshare&utm_medium=link&utm_source=publishsharelink&mode=preview

https://www.canva.com/design/DAGCpx7MjR4/Avhb8_8W-LBg_0Xidz1R0A/view?utm_content=DAGCpx7MjR4&utm_campaign=designshare&utm_medium=link&utm_source=publishsharelink&mode=preview